CG
TXMD icon

Cutler Group’s TherapeuticsMD TXMD Stock Holding History

Cutler Group’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-78
Closed -$4K – 5241
2017
Q4 		$4K Sell
78
-116
-60% -$32.3K ﹤0.01% 3839
2017
Q3 		$21K Sell
194
-150
-44% -$43.4K ﹤0.01% 3105
2017
Q2 		$80K Sell
344
-748
-68% -$187K ﹤0.01% 2058
2017
Q1 		$73K Sell
1,092
-2,094
-66% -$648K ﹤0.01% 2045
2016
Q4 		$96K Buy
+3,186
New +$987K ﹤0.01% 1947
2016
Q2 		– Sell
-122
Closed -$2K – 7317
2016
Q1 		$2K Buy
+122
New +$41.6K ﹤0.01% 5681

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's TXMD Position: Q3 2023 in Review

Cutler Group sold out of TherapeuticsMD (TXMD) in Q3 2023, closing a stake of 100 shares.

Cutler Group first reported a position in TXMD in Q4 2015 and held it in 16 quarters. The position peaked at $260K in Q2 2017. 36 funds tracked by Wall St. Rank hold TXMD as of Q3 2023.

  • Cutler Group reported no remaining TherapeuticsMD position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 100 TherapeuticsMD shares in Q3 2023.
  • Cutler Group first reported a position in TherapeuticsMD in Q4 2015 and held it in 16 quarters.
  • Cutler Group's TherapeuticsMD position peaked at $260K in Q2 2017.
  • 36 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.